This second edition features the latest data for lipids, hypertension and overall risk reduction plus a new chapter on incretins, amylin analogues and DPP-IV inhibitors. It includes an expanded section on lipid disorders in the diabetic patient.
This second edition features the latest data for lipids, hypertension and overall risk reduction plus a new chapter on incretins, amylin analogues and...